Telix Pharmaceuticals Ltd (ASX: TLX) shares are charging higher today.

Shares in the S&P/ASX 200 Index (ASX: XJO) diagnostic and therapeutic product developer closed yesterday trading for $13.64. In early morning trade on Friday, shares are changing hands for $14.14 apiece, up 3.7%.

For some context, the ASX 200 is down 0.6% at this same time.

With today’s intraday lift factored in, Telix shares are now up an impressive 31.4% since market close on 11 March.

Here’s what’s piquing ASX investor interest today.

Telix shares jump on FDA acceptance

Telix shares are marching higher after the company announced that the United States Food and Drug Administration (FDA) has accepted its resubmitted New Drug Application (NDA) for TLX101-Px1.

TLX101-Px1, or Pixclara, is the company’s glioma (brain cancer) imaging agent.

The FDA is aiming for a Prescription Drug User Fee Act (PDUFA) date on 11 September.

That date is achievable, as Pixclara holds both Orphan Drug and Fast Track designations in the US.

The company said that the FDA approval of Pixclara will help meet the significant unaddressed medical need for the characterisation of recurrent or progressive glioma from treatment-related changes in both adult and paediatric patients.

Telix noted that neuroimaging of glioma with 18F-FET (a radioactive imaging tracer) is already broadly recommended in international clinical practice guidelines.

FDA approval would open up the huge US medical market for Pixclara. However, Telix said it is not yet including any potential revenue from future sales in its full-year FY 2026 financial guidance.

What did management say?

“The FDA’s acceptance of our NDA resubmission is an important milestone for Telix,” Kevin Richardson, CEO Telix Precision Medicine, said. “We appreciate the FDA’s constructive engagement and look forward to working closely with the Agency to urgently obtain approval and then bring this product to market for the benefit of patients.”

Commenting on the FDA acceptance helping to boost Telix shares today, Thomas Hope – Vice Chair, Department of Radiology and Biomedical Imaging at the University of California, San Francisco – said:

There remains a critical unmet need in improving our ability to image residual glioma after treatment. We have worked with Telix for the last three years to help leverage our clinical data to help make FET-PET9 available to patients in the United States.

Patrick Wen, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, added:

Distinguishing tumour progression from treatment-related change remains one of the most challenging aspects of glioma care. PET imaging with 18F-FET is an important tool in clinical practice worldwide, and the FDA’s acceptance of this application is a meaningful step toward broader access for patients and clinicians in the United States.

With today’s intraday gains factored in, Telix shares remain down 46.8% over 12 months.

The post Up 31% in a month, why are Telix shares lifting off again on Friday? appeared first on The Motley Fool Australia.

More reading

• Where is the value amongst ASX healthcare shares?
• Telix Pharmaceuticals: FDA accepts Pixclara NDA
• Top brokers name 3 ASX shares to buy today
• 5 things to watch on the ASX 200 on Wednesday
• Why rebounding Telix shares could still rise 40%

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Magellan Financial Group Ltd (ASX: MFG) share price is in focus following news of a proposed full merger with Barrenjoey Capital Partners Group Holdings. The company highlighted its increased stake and support from shareholders for the transaction.

What did Magellan Financial Group report?

• Magellan will acquire the remaining shares in Barrenjoey Capital Partners, increasing its ownership to 100%
• The merger values Barrenjoey at $1.616 billion on a 100% basis
• Barrenjoey delivered $108 million in NPATA (Net Profit After Tax and Amortisation) over the last twelve months to December 2025
• Last twelve months’ revenue for the combined group amounted to $313 million, with Magellan managing $37.5 billion in assets as at 31 March 2026
• Shareholders strongly supported the share issuance, with 91.2% voting in favour

What else do investors need to know?

The merger will unify the businesses, broadening Magellan’s service offering in advisory, capital markets, equities, research, and private capital. Magellan lifted its economic interest in Barrenjoey to 46.4% after purchasing an extra ~10% from Barclays in March 2026, funded via an institutional placement and oversubscribed Share Purchase Plan (SPP).

The Share Purchase Plan saw significant demand, with scale-backs applied to ensure a fair allocation for all eligible investors. The combined group is aiming for a stronger, diversified platform with global reach and a sharpened focus on client outcomes.

What’s next for Magellan Financial Group?

Completion of the merger is subject to several conditions, including regulatory and shareholder approvals, but is progressing with strong support. Management expects the merged group will have enhanced career opportunities, increased scale, and improved balance sheet resilience to navigate market cycles.

Looking ahead, Magellan plans to accelerate growth across public and private markets while leveraging both companies’ expertise and client relationships. The board sees the merger as a compelling case for long-term value creation.

Magellan Financial Group share price snapshot

Over the past 12 months, Magellan Financial Group shares have risen 28%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.

View Original Announcement

The post Magellan Financial Group shares in focus following Barrenjoey merger approval appeared first on The Motley Fool Australia.

More reading

• Monadelphous wins $145m of new and renewed resources sector contracts
• Fortescue accelerates world’s first large-scale industrial green energy grid
• Telix Pharmaceuticals: FDA accepts Pixclara NDA
• 7 ASX 200 shares just upgraded to strong buy ratings
• 5 things to watch on the ASX 200 on Friday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Northern Star Resources Ltd (ASX: NST) shares are a popular option for investors looking for exposure to the gold sector.

But are they a good option after falling heavily from their highs? Let’s see what Bell Potter is saying.

What is the broker saying?

Bell Potter highlights that Northern Star will be releasing its eagerly anticipated quarterly update this month.

While the miner’s production numbers for the third quarter are now known, its costs will be the main focal point. The broker sees risks that management will be forced to downgrade its cost guidance for FY 2026. It said:

NST announced last week it had produced 381koz over the 3Q (+10% QoQ, VA 366koz BPe 353koz), despite the headwinds highlighted in the Mar-13 downgrade. NST are now 74% through the revised production guidance of 1,500koz, which requires a result of at least 391koz (+2.3% QoQ) to meet the twice revised guidance. On our numbers, that will still require a material lift across the portfolio, particularly in throughput and grade at KCGM. The pre-reported result was a beat on our estimates and consensus for 3Q, and, whilst we still anticipate production at the low end of guidance there may be signs that NST has hit the bottom of the downgrade cycle.

Fuel costs will present a headwind heading into the 4Q, accounting for ~5% of AISC prior to the Middle East conflict. We continue to see risks that the AISC guidance of A$2,600/oz – $2,800/oz is at risk given the recent production guidance downgrade (~100koz) and the increase in fuel costs expected to impact the 4Q result. We suspect NST, much like peers in the space, will pull as many levers as possible to prioritise high-value tonnes and delaying any non-essential waste movement, to manage the near-term impacts.

Outside this, the broker highlights that Northern Star’s $500 million share buyback could be interpreted as a sign of confidence from management. It adds:

NST announced the commencement of an on market Buy-back scheme of up to A$500m, representing ~1.6% of issued capital. The buy-back is separate from the dividend payout policy of 20-30% of cash earnings and will commence on the 23rd of April. The buy-back has minimal impact on our EPS estimates going forward, however the signalling of value in the underlying business is of more importance. As noted above, we see NST as hitting the bottom of production and earnings downgrades, with some margin compression to come from the impact of fuel prices.

Should you buy Northern Star shares?

According to the note, the broker has retained its buy rating and $35.00 price target on Northern Star’s shares.

Based on its current share price of $24.47, this implies potential upside of 43% for investors over the next 12 months.

In addition, the broker is expecting a 2.6% dividend yield over the period, boosting the total potential return beyond 45%.

The post Are Northern Star shares a cheap buy? appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Friday
• March was the worst month for the gold price since June 2013. Now what?
• 5 things to watch on the ASX 200 on Thursday
• 5 things to watch on the ASX 200 on Wednesday
• Why Greatland Resources, Newmont, Northern Star, and Qantas shares are rising today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

In what has been a volatile start to 2026, ASX healthcare shares have been amongst the sharemarket losers. 

The S&P/ASX 200 Health Care Index (ASX: XHJ) has fallen almost 17% year to date. 

However, there are opportunities to find value for investors. 

Let’s look at three ASX healthcare shares drawing positive outlooks from experts. 

Telix Pharmaceuticals Ltd (ASX: TLX)

Telix is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic (‘theranostic’) products using targeted radiation. 

This process treats cancerous or diseased cells, an alternative approach to many cancer therapies, which also attack healthy tissue at the same time.

Telix shares have rebounded over the past couple of months, rising 55% since mid February. 

Telix shares rose in March largely because several value-driving catalysts hit at once, improving both fundamentals and investor sentiment.

However, they remain down 48% over the last year. 

In good news for investors, brokers are expecting Telix shares to recover even further. 

Recently, Bell Potter retained its buy rating and $19 price target on this radiopharmaceuticals company’s shares. 

From yesterday’s closing price of $13.64, this indicates a further upside of roughly 39%. 

Mayne Pharma Group Ltd (ASX: MYX)

Mayne Pharma Group is another ASX healthcare stock that is down significantly from yearly highs. 

It has fallen 32% year to date. 

This includes a 6% decline yesterday, as investors may have reacted negatively to fresh tariff worries.

However, the company is confident the new tariffs will have “no material impact” on its FY27 earnings profile.

The stock price closed yesterday at $2.16, and after the recent fall, it may be another value play.

Two analysts’ forecasts via TradingView have an average one-year price target of $5.75 on the stock, indicating more than 160% upside. 

EBR Systems Inc (ASX: EBR)

EBR Systems Inc is engaged in treatment for patients suffering from cardiac rhythm diseases by developing therapies using wireless cardiac stimulation. 

The company’s Wise CRT System uses proprietary wireless technology to deliver pacing stimulation directly inside the left ventricle of the heart.

It is down roughly 30% year to date. However, it is also drawing positive ratings from brokers. 

Yesterday, the company released a preliminary version of its operating metrics. 

The report showed strong Q1 2026 growth in commercial cases.

This prompted Bell Potter to release updated guidance on this ASX healthcare stock along with a price target of $2, indicating a potential 194% rise. 

The post Where is the value amongst ASX healthcare shares? appeared first on The Motley Fool Australia.

More reading

• Telix Pharmaceuticals: FDA accepts Pixclara NDA
• Bell Potter says this ASX healthcare stock could rise nearly 200%
• Why Bendigo Bank, EBR Systems, Strickland, and Woodside shares are rising today
• Top brokers name 3 ASX shares to buy today
• 5 things to watch on the ASX 200 on Wednesday

Motley Fool contributor Aaron Bell has positions in Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Monadelphous Group Ltd (ASX: MND) share price is in focus after the company reported it has secured approximately $145 million in new contracts and contract extensions in the resources sector. Highlights include a major project at Rio Tinto’s (ASX: RIO) Paraburdoo iron ore mine and contract extensions at BHP Group Ltd (ASX: BHO) and Queensland Alumina Limited.

What did Monadelphous report?

• New contracts and extensions valued at around $145 million in total
• Secured a Rio Tinto construction project at Paraburdoo iron ore mine in WA
• Two-year extension to Olympic Dam maintenance contract with BHP in SA
• Two-year extension and expanded scope at Queensland Alumina Limited in QLD
• New construction contract with Harmony Gold at Hidden Valley Gold Mine, PNG

What else do investors need to know?

Monadelphous’ work for Rio Tinto at Paraburdoo involves installing a new dust collector and ventilation system for coarse ore stockpile tunnels, with completion expected in early 2027. The company’s relationship with BHP has also been extended, covering mechanical and electrical maintenance, planned shutdowns, and project services at Olympic Dam.

At Queensland Alumina in Gladstone, Monadelphous has secured both a contract extension and expanded responsibilities, now including demolition and power generation activities. The company’s expertise in the sector is reinforced by more than 30 years of service at this site.

What’s next for Monadelphous?

Looking ahead, Monadelphous plans to deliver on these newly awarded and extended contracts while continuing to grow its presence in resources, energy, and infrastructure markets. The company remains focused on leveraging its long-standing client relationships and diversified capabilities to pursue further opportunities, both domestically and internationally.

Monadelphous share price snapshot

Over the past 12 months, Monadelphous shares have risen 100%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.

View Original Announcement

The post Monadelphous wins $145m of new and renewed resources sector contracts appeared first on The Motley Fool Australia.

More reading

• Fortescue accelerates world’s first large-scale industrial green energy grid
• Telix Pharmaceuticals: FDA accepts Pixclara NDA
• 7 ASX 200 shares just upgraded to strong buy ratings
• 5 things to watch on the ASX 200 on Friday
• Buy, hold, or sell? South32, Capstone Copper, and BHP shares

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Fortescue Ltd (ASX: FMG) share price is in the spotlight after the company announced it is fast-tracking the delivery of the world’s first large-scale, integrated green energy grid for heavy industry. Fortescue expects to eliminate diesel use ahead of its previous targets and is projecting significant cost savings from its decarbonisation program.

What did Fortescue report?

• Accelerating its green industrial energy grid, targeting completion by end of 2028
• 290MW of renewable capacity to be installed by early next year, powering “green processing” at Pilbara sites
• Full grid to include 1.2GW of solar, over 600MW wind, and 4–5GWh battery storage
• Targeting approximately 2GW total generation capacity upon program completion
• Forecasting US$100 million in fossil fuel cost savings by next year
• Anticipated C1 unit cost reduction of at least US$2–$4/wet metric tonne

What else do investors need to know?

Fortescue’s grid operates off-grid, using its own renewable generation rather than relying on national networks, supporting industrial operations around the clock. The project leverages proprietary AI-driven optimisation, in-house developed technology, and aims to demonstrate the commercial and operational advantages of full decarbonisation in mining.

The company plans to expand capacity by an extra 2GW, with advanced batteries, at a capital cost below US$2.5 billion if future investment decisions proceed. Fortescue will offer its systems as licences or services globally and has received early interest from other large shippers and countries.

What’s next for Fortescue?

With construction underway, Fortescue expects its Pilbara green grid to power all operations for 24-hour periods fossil fuel–free by late next year. Longer-term, the company is targeting full completion by the end of 2028, reducing cost volatility and improving energy certainty.

Fortescue intends to replicate this green grid technology globally, anticipating accelerated timelines and reduced costs with further deployments. The company is positioning to license or provide its end-to-end green energy system to major industrial energy users worldwide.

Fortescue share price snapshot

Over the past 12 months, Fortescue shares have risen 36%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.

View Original Announcement

The post Fortescue accelerates world’s first large-scale industrial green energy grid appeared first on The Motley Fool Australia.

More reading

• Monadelphous wins $145m of new and renewed resources sector contracts
• Telix Pharmaceuticals: FDA accepts Pixclara NDA
• 7 ASX 200 shares just upgraded to strong buy ratings
• 5 things to watch on the ASX 200 on Friday
• Orora updates FY26 outlook as Saverglass earnings take a hit

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in the spotlight after the FDA accepted its New Drug Application for TLX101-Px (Pixclara®), a PET imaging agent for glioma. TLX101-Px has received Orphan Drug and Fast Track status, with a key regulatory decision expected by September.

What did Telix Pharmaceuticals report?

• The US FDA accepted Telix’s NDA for TLX101-Px (Pixclara®), a PET agent for imaging brain cancer (glioma)
• The Prescription Drug User Fee Act (PDUFA) goal date is 11 September 2026
• TLX101-Px holds Orphan Drug and Fast Track designations in the US
• No FY 2026 revenue guidance has been assigned to TLX101-Px pending approval
• TLX101-Px aimed at addressing an unmet medical need in both adult and paediatric glioma cases

What else do investors need to know?

The FDA’s acceptance of the Telix NDA marks a key step toward potential commercialisation of TLX101-Px in the United States. This diagnostic agent aims to improve the differentiation between recurrent glioma and treatment-related changes, a persistent challenge in neuro-oncology.

TLX101-Px is expected to complement Telix’s broader LAT1-targeting therapeutic pipeline, notably the TLX101-Tx therapy under investigation in the IPAX-BrIGHT clinical trial. There are currently no marketing authorisations for TLX101-Px or TLX101-Tx in any region.

Telix has reaffirmed that FY 2026 guidance does not anticipate revenue for TLX101-Px, pending the FDA decision. The product could provide both clinical impact and financial upside if approved in the future.

What’s next for Telix Pharmaceuticals?

Investors can expect further updates as Telix works with the FDA ahead of the September 2026 goal date for TLX101-Px. The company is also advancing late-stage trials for related therapies, aiming to build a broader radiopharmaceutical portfolio for oncology and rare diseases.

Looking ahead, a successful approval could see Telix expand its presence in the US diagnostics market while pursuing commercial opportunities for both imaging and therapeutic candidates.

Telix Pharmaceuticals share price snapshot

Over the past year, Telix Pharmaceuticals shares have declined 49%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.

View Original Announcement

The post Telix Pharmaceuticals: FDA accepts Pixclara NDA appeared first on The Motley Fool Australia.

More reading

• Where is the value amongst ASX healthcare shares?
• Monadelphous wins $145m of new and renewed resources sector contracts
• Fortescue accelerates world’s first large-scale industrial green energy grid
• 7 ASX 200 shares just upgraded to strong buy ratings
• 5 things to watch on the ASX 200 on Friday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

I think putting money to work in the share market is always a good idea.

Regardless of the amount, what matters most is choosing businesses with strong long-term potential and building the habit of investing consistently.

The good news is that the Australian share market is home to many businesses that tick these boxes in 2026.

So, if I had $2,000 to invest today, these are three ASX shares I would consider buying in April.

Breville Group Ltd (ASX: BRG)

Breville is a business I think is often underestimated. It operates in premium kitchen appliances, but what stands out to me is how it has built a global brand. Its products are sold across multiple regions, and it continues to expand into new markets.

What I like is the combination of product innovation and international growth. The company has shown it can introduce new products that resonate with consumers while also scaling its distribution globally.

That gives it multiple avenues for growth over time.

Xero Ltd (ASX: XRO)

Xero offers exposure to software and digital transformation. The company provides accounting software to small and medium-sized businesses, and that shift toward cloud-based solutions is still ongoing.

The share price has been under pressure, partly due to concerns around competition and artificial intelligence (AI). But I think the long-term opportunity remains intact.

Xero has built a strong ecosystem and continues to grow its subscriber base, which supports recurring revenue. For me, it is a business that could continue compounding if it executes well.

Pro Medicus Ltd (ASX: PME)

Pro Medicus is one of the more impressive growth stories on the ASX. It operates in the medical imaging software market, providing solutions to hospitals and healthcare providers worldwide.

What stands out is the quality of the business. High margins, strong cash flow, and a growing list of major contracts all point to a company that is scaling effectively.

Healthcare demand is also supported by long-term trends, which give it a favourable backdrop.

Its valuation can look demanding at times, but I think that reflects the strength of the business and its positive long-term growth outlook.

Foolish Takeaway

A $2,000 investment can be the start of something meaningful.

Breville offers global consumer growth, Xero provides exposure to software and recurring revenue, and Pro Medicus brings high-quality healthcare growth.

Importantly, all three have the potential to grow over time, and that is what matters most to me when putting money to work.

The post $2,000 to invest? 3 ASX shares to consider today appeared first on The Motley Fool Australia.

More reading

• 7 ASX 200 shares just upgraded to strong buy ratings
• 3 reasons to buy Xero shares now
• 2 ASX 200 shares I rate as top buys for growth
• I’m following Warren Buffett to snap up these cheap ASX stocks
• 3 ASX shares tipped to grow 100% or more in the next 12 months

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX healthcare stock EBR Systems Inc (ASX: EBR) is under the spotlight today after a new announcement sent the stock price surging on Thursday.

EBR is a clinical stage company that has developed its patented Wireless Stimulation Endocardially (WiSE) technology for the treatment of cardiac rhythm disease and to eliminate the need for cardiac pacing leads when delivering cardiac resynchronisation therapy. 

The healthcare stock rose roughly 7% yesterday after the company released an announcement to the ASX.

What did EBR systems announce?

Yesterday, the ASX healthcare stock released a preliminary version of its operating metrics earlier than scheduled by its quarterly reporting time frame (mid-May). 

According to Bell Potter, it is no surprise EBR has provided an early release as it gears up toward an eventual and large capital raising.

In yesterday’s report, the company said it saw strong Q1 2026 growth in commercial cases. 

It reported: 

• Robust commercial momentum continued through Q1 2026 with case volumes more than doubling from Q4 2025
• The WiSE® System was successfully implanted in 41 commercial patients during the quarter, bringing total
• implants across the pilot phase and Limited Market Release to 71
• EBR expects to report revenue in the range of US$2.25M to US$2.36M for Q1 2026, based on preliminary unaudited quarter-end results and subject to quarter-end closing adjustments. 

John McCutcheon, EBR Systems’ President & Chief Executive Officer said: 

In Q1 2026, we made impressive progress across both our commercial and clinical programs. Case volumes increased strongly during the quarter, reflecting growing physician experience, expanding site readiness and the steady execution of our Limited Market Release. We also continued to advance important clinical initiatives, with further enrolment in both the WiSE-UP post-approval study and the TLC-AU feasibility study, helping to expand the body of evidence supporting the WiSE System across a broader patient population. We are encouraged by the momentum we are seeing and remain focused on disciplined execution, physician training, site activation and building the clinical and commercial foundation for broader adoption of the WiSE System.

What did Bell Potter have to say?

Following the release, the team at Bell Potter released updated guidance on the ASX healthcare stock. 

The broker said the data continues to impress, with implants more than doubling to quarter of quarter to 41.

The success in implant volume is supported by the growing breadth of physicians trained and hospital contracts signed. A further 22 Physicians trained on the WiSE pacing system and 16 hospital contracts signed in the quarter, bringing the cumulative totals to 55 & 37. EBR appear be tracking well toward our hospital target of 60 for FY26.

Big upside for this ASX healthcare stock

Bell Potter has maintained its buy recommendation for EBR Systems, along with a price target of $2.00. 

From yesterday’s closing price of $0.68, that indicates a potential upside of 194%. 

It is not surprising that the market has reacted well to the data release, and with each data release we grow more confident in EBR’s commercial prospects and expect the market to do so as well.

The post Bell Potter says this ASX healthcare stock could rise nearly 200% appeared first on The Motley Fool Australia.

More reading

• Why Bendigo Bank, EBR Systems, Strickland, and Woodside shares are rising today
• Experts name 2 ASX financials stocks to watch closely
• 3 ASX penny stocks drawing positive ratings from experts
• Guess which ASX stock could more than triple in value according to Morgans!
• Is now the time to jump on these ASX real estate stocks?

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Treasury Wine Estates Ltd (ASX: TWE) just can’t catch a break.

The wine giant behind premium brands like Penfolds slipped another 1% on Thursday and is now down roughly 25% year to date and a staggering 53% over the past 12 months. Unfortunately, this kind of underperformance isn’t new for long-suffering shareholders.

So, is the ASX wine stock a hidden gem emerging or a classic value trap?

What’s been going on?

Treasury Wine shares have been battling a cocktail of challenges.

From shifting global demand to premiumisation risks and supply chain pressures, the business has struggled to regain investor confidence. But one issue is drawing particular scrutiny right now: inventory.

Broker Ord Minnett recently highlighted concerns around tight grape supply contracts in both the US and Australia. These agreements are expected to keep inventory levels elevated for longer than previously anticipated.

According to the broker:

Combined, the impact of these contract terms means Ord Minnett estimates Treasury’s inventory will increase again in FY27 before scaling down in the following years.

Size-wise, we see inventory topping out at circa $2.9 billion, a whisker away from the company’s current market capitalisation and twice the inventory size it held a decade ago.

Big red flag

That’s a big red flag for this blue chip. High inventory levels can tie up capital, pressure margins, and signal weaker-than-expected demand.

In response, Ord Minnett has increased its debt assumptions and trimmed its price target from $5.00 to $4.50. It also upgraded its recommendation, but only to hold from lighten. The broker noted the sharp recent selloff of Treasury Wine shares, including an 18% slide in March and close to a 25% drop year to date.

Even at the reduced target, that implies only around 14% upside from current levels.

Analyst snapshot: cautious at best

Ord Minnett’s view isn’t an outlier. Across the market, most brokers are sitting on the fence. The consensus rating on Treasury Wine shares is broadly a hold, reflecting a balance between long-term brand strength and near-term uncertainty.

The average price target sits around $5.24, suggesting potential upside of roughly 33%. That may sound appealing, but it also highlights the lack of conviction. This isn’t a stock analysts are rushing to back aggressively.

Foolish Takeaway

There’s no denying Treasury Wine owns a portfolio of premium brands and has global reach. Those strengths could pay off over time.

But right now, the risks are hard to ignore. Elevated inventory, rising debt assumptions, and patchy demand trends are weighing on sentiment. And while the share price fall is eye-catching, it hasn’t yet triggered widespread bullishness among brokers.

For investors, that puts Treasury Wine shares in a tricky middle ground. It might offer value, but it’s far from a clear-cut bargain.

The post Down 53%, are Treasury Wine shares a true gem or a value trap? appeared first on The Motley Fool Australia.

More reading

• Buy, hold, or sell? Treasury Wine, Domino’s Pizza, and Telstra shares
• These are the 10 most shorted ASX shares
• Treasury Wine shares hit 10-year lows last week. So why are buyers stepping in now?
• These are the 10 most shorted ASX shares
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Treasury Wine Estates. The Motley Fool Australia has positions in and has recommended Treasury Wine Estates. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.